Editorial: Legal delays may be a plus for state's stem-cell effort
By San Jose Mercury News,
San Jose Mercury News
| 06. 01. 2006
The delays in implementing California's ambitious stem-cell initiative -- primarily the result of litigation that borders on being nuisance suits -- have been immensely irritating to those wanting to push forward with basic research.
But the delay has had the side benefit of allowing the stem-cell agency to solidify its planning, structure and regulations. That in turn enhances the chances that when research dollars start flowing at the rate of nearly $300 million a year, the state will have a program in place that delivers on its ambitious promises.
Once rid of legal challenges to Proposition 71, hopefully by next spring, California can start to dole out in a single year more than the National Institutes of Health have granted for stem-cell research in this decade. So far, only a trickle of the promised $3 billion in bonds has flowed from the state to scientists.
The delays also give the state time to resolve its remaining legislative oversight issues. State Sen. Deborah Ortiz, D-Sacramento, took a big step in that direction when she wisely agreed to withdraw a bill that...
Related Articles
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Ed Pilkington, The Guardian | 06.12.2026
Desperate US parents paying up to $20,000 a session for a procedure scientists say could be bogus
Autistic children as young as 18 months old are being injected with human stem cells derived from umbilical cords in unapproved, unproven and...
By Tobi Thomas, The Guardian | 06.10.2026
The UK’s stem cell transplant system is potentially putting the lives of blood cancer patients at risk as a result of inadequate infrastructure and a lack of long-term planning, a parliamentary report has found.
A hematopoietic stem cell transplant, often...